Embryonic stem (ES) cells deficient in the enzyme poly(ADP-ribose) polymerase (Parp1) develop into teratocarcinoma-like tumors when injected subcutaneously into nude mice that contain cells with giant cell-like morphology. We show here that these cells express genes characteristic of trophoblast giant cells and thus belong to the trophectoderm lineage. In addition, Parp1 Ϫ/Ϫ tumors contained other trophoblast subtypes as revealed by expression of spongiotrophoblast-specific marker genes. The extent of giant cell differentiation was enhanced, however, as compared with spongiotrophoblast. A similar shift toward trophoblast giant cell differentiation was observed in cultures of Parp1-deficient ES cells and in placentae of Parp1 Ϫ/Ϫ embryos. Analysis of other cell lineage markers demonstrated that Parp1 acts exclusively in trophoblast to suppress differentiation. Surprisingly, trophoblast derivatives were also detected in wildtype tumors and cultured ES cells, albeit at significantly lower frequency. These data show that wildtype ES cells contain a small population of cells with trophectoderm potential and that absence of Parp1 renders ES cells more susceptible to adopting a trophoblast phenotype.
Introduction
During mouse embryogenesis, the trophectoderm cell lineage separates from the inner cell mass (ICM) at the blastocyst stage and contributes exclusively to extraembryonic tissues. In contrast, the ICM (from which ES cells are derived) gives rise to the embryo proper as well as to extraembryonic mesoderm (Hogan et al., 1986) . After fertilization, trophoblast giant cells are the first cells that differentiate from the mural trophectoderm and mediate implantation into the uterine wall. In contrast, polar trophectoderm cells in contact with the ICM continue to proliferate and give rise to the trophoblast stem (TS) cells that mainly reside in the extraembryonic (chorionic) ectoderm (Cross, 2000) . TS cells leaving the chorionic ectoderm form the ectoplacental cone, a structure that contains diploid trophoblast cells at an intermediate stage of differentiation and which contributes mainly to formation of the spongiotrophoblast (Cross, 2000) . Cells at the margins of the ectoplacental cone continue to differentiate and form (secondary) trophoblast giant cells.
ES and TS cell lineages are believed to be strictly separated and controlled by different signal transduction pathways (Rossant, 2001) . However, cells with trophoblast giant cell-like morphology form in teratocarcinoma-like tumors derived from the subcutaneous injection of ES cells that are deficient in the nuclear enzyme poly(ADP-ribose) polymer- ase (Parp1) . The differentiation of embryonic cell lineages occurred normally in the Parp1
tumors. Parp1 is a highly conserved, constitutively expressed factor that is localized to chromosomes and centrosomes (Kanai et al., 2000) and is important for maintenance of genomic integrity (de Murcia and Ménissier-de Murcia, 1994) . Parp1-deficient mice are viable and fertile, but show an increased sensitivity to alkylating agents and ␥-irradiation (Masutani et al., 2000; Ménissier-de Murcia et al., 1997) . Embryonic fibroblasts derived from Parp1 Ϫ/Ϫ mice contain a genomically unstable tetraploid population (Simbulan-Rosenthal et al., 1999) , and spontaneously immortalized embryonic fibroblasts show hyperploidy (Nozaki et al., 2001) . As a consequence of its activation at sites of DNA breakage, Parp1 also contributes to cell death induction by depleting the cell of energy sources (Ha and Snyder, 1999) . Apart from its function in DNA damage control, Parp1 is involved in the regulation of gene expression and cell differentiation (Bauer et al., 1995; Ohashi et al., 1984) . Parp1-deficiency causes misregulation of genes involved in cell cycle control, DNA replication, and chromosome processing or assembly (Simbulan-Rosenthal et al., 2000) .
The unexpected finding of cells with trophoblast giant cell-like appearance that differentiated from Parp1 Ϫ/Ϫ ES cells in teratocarcinoma-like tumors raised several questions that were addressed in the present study: (1) Do these enlarged cells express typical markers of trophoblast giant cells? (2) Are other trophoblast subtypes present in Parp1 Ϫ/Ϫ tumors and does Parp1-deficiency cause an equal increase of different trophoblast cell types? (3) Is trophoblast differentiation dependent on the in vivo environment of the tumors or does it also occur in cultured ES cells in vitro?
To investigate these questions, we took advantage of several marker genes that are exclusively expressed in trophectoderm. Trophoblast stem cell markers that become restricted to this lineage at the blastocyst stage are the transcription factor genes Cdx2 (Beck et al., 1995) , Esrrb (Luo et al., 1997) , and Eomes (Hancock et al., 1999) . Expression of genes restricted to ectoplacental cone and spongiotrophoblast include Tpbp (initially named 4311) (Lescisin et al., 1988) and Mash2 (Guillemot et al., 1994) . Trophoblast giant cells synthesize several members of the prolactin hormone family. Placental lactogen I (Pl1) and II (Pl2) are expressed in early-and late-stage giant cells, respectively (Carney et al., 1993) . Prolactin-like protein A (Prlpa) is highly expressed in secondary trophoblast giant cells (Muller et al., 1998) . Proliferin (Plf) expression overlaps Pl1-, Prlpa-, and Pl2-synthesis and peaks around midgestation (Lee et al., 1988) . Proliferin-related protein (Plfr) is a late-stage giant cell marker, but Plfr expression is also found in spongiotrophoblast cells (Carney et al., 1993) . Using these markers, we detected expression of genes characteristic of both spongiotrophoblast and trophoblast giant cells in Parp1 Ϫ/Ϫ tumors. We also detected trophoblastspecific gene expression in wildtype tumors, albeit at a significantly lower level. A similar difference in trophoblast contribution was observed in cultured ES cells. These results demonstrate the ability of ICM-derived ES cells to differentiate into trophoblast and reveal a role for Parp1 in early cell lineage definition.
Materials and methods

Embryos and tumor samples
Parp1
Ϫ/Ϫ and wildtype embryos derived from matings of Parp1 Ϫ/Ϫ and wildtype mouse lines on a mixed ICR/ 129Sv genetic background were transferred into the oviduct of ICR wildtype and Parp1 Ϫ/Ϫ recipients on day 0.5 of pseudopregnancy as described previously (Suzuki et al., 1994) . Conceptuses were collected at embryonic days (E) 8.5, 11.5, and 13.5 (counting the day of the vaginal plug as day 0.5). Whole conceptuses (E8.5, E11.5) or placentae (E13.5) were fixed overnight in 10% formalin and processed for paraffin histology.
Teratocarcinoma-like tumors derived from ES cell lines J1 (wildtype) and 210-58 (Parp1 Ϫ/Ϫ ) described in and other sets of tumors prepared similarly were used for histological analysis. Briefly, aliquots of 2 ϫ 10 8 cells were injected subcutaneously into both flanks of 8-week-old female BALB/c nu/nu mice (CLEA Japan, Tokyo). Three weeks after injection, mice were euthanized and tumors were fixed in 10% formalin overnight and processed for routine paraffin histology.
ES cell cultures
ES cell lines J1 and 210-58 were routinely maintained on embryonic fibroblast feeder layers in standard ES medium containing 10% FBS, 1 mM sodium pyruvate 5.5 ϫ 10 Ϫ6 M ␤-mercaptoethanol, 0.1 mM MEM nonessential amino acids and 5 ϫ 10 5 U/ml leukemia inhibitory factor in DMEM (Invitrogen). For trophoblast differentiation tests, ES cells were grown for 3-7 days on gelatin-coated dishes without feeder cell layers in ES cell medium, ES cell medium containing 10 ng/ml basic fibroblast growth factor (bFGF; Sigma), standard TS cell medium (Tanaka et al., 1998) , and differentiating TS cell medium. Standard TS cell medium contained 20% FBS, 1 mM sodium pyruvate, 5.5 ϫ 10 Ϫ6 M ␤-mercaptoethanol and 10 ng/ml bFGF in RPMI 1640 (Invitrogen), with 70% of the medium being preconditioned by incubation on embryonic fibroblasts. Differentiating TS cell medium consisted of 20% FBS, 1 mM sodium pyruvate, 5.5 ϫ 10 Ϫ6 M ␤-mercaptoethanol in RPMI 1640 only.
RNA preparation and Northern blot hybridization
Total RNA from ES cell cultures was prepared by using Trizol Reagent (Invitrogen), and 15-20 g were electrophoresed in 1.2% formaldehyde agarose gels and blotted onto GeneScreen Nylon membrane (NEN Life Science Products). Random-primed DNA labeling was carried out with 30 Ci of 32 P-dCTP, and Northern blot hybridizations were performed by using standard conditions (Sambrook et al., 1989) .
RNase protection assay
Total RNA (20 g) was analyzed with 32 P-UTP-labeled riboprobes using standard procedures (Yamamoto et al., 1998) . Protected fragments were resolved by acrylamide gel electrophoresis and detected by autoradiography.
Oligonucleotide microarray analysis
Wildtype and Parp1
Ϫ/Ϫ ES cells were cultured in the absence of feeder cells for 6 days with one passage in the presence of LIF. Expression levels of wildtype and Parp1 Ϫ/Ϫ ES cells were examined by GeneChip [Affimetrix, Murine Genome U74Av2, containing a total of 12,488 genes and expressed sequence tags (ESTs)] analysis. Array hybridizations were performed in triplicate by using cDNA synthesized independently from wildtype and Parp1 Ϫ/Ϫ ES cell mRNA. Average hybridization intensity for each array was scaled to 1000 in order to compare multiple arrays. The data were then analyzed by GeneSpring 4.2 (Silicon Genetics).
In situ hybridization
In situ hybridizations were carried out with digoxigeninlabeled riboprobes (Roche). For paraffin sections, standard procedures were applied and signals were detected by using an anti-digoxigenin-alkaline phosphatase-conjugated antibody (Roche). Staining was carried out overnight by using NBT and BCIP (Roche). For cell cultures, 5 ϫ 10 5 ES cells/well were plated onto gelatin-coated coverslips in sixwell dishes and grown for 5 days under the conditions described (ES, ES ϩ bFGF, TS, diff. TS). Statistical analysis (t test) was performed for cells grown under standard ES cell conditions. For each experiment and cell line, cells from one to three coverslips were trypsinized and counted to determine the total number of cells/coverslip. Cells grown in parallel were processed for in situ hybridization. Detection was performed as above with BCIP/NBT staining for 7-9 h.
Results
Trophoblast subtypes in ES cell-derived tumors
To characterize the giant cells that formed in Parp1-deficient teratocarcinoma-like tumors, we analyzed the expression of trophoblast giant cell-specific marker genes Pl1, Plf, Plfr, and Pl2. Expression of all genes was detected and was localized to cells with characteristic giant cell morphology (Fig. 1 ). Pl1 and Pl2 mRNAs were confined to different subsets of cells within large giant cell clusters, thus distinguishing early and late stages of giant cell differentiation (Fig. 1E, H, I , and L). Plf-expressing cells were the most frequently detected in Parp1 Ϫ/Ϫ tumors overlapping both Pl1-and Pl2-positive cell populations consistent with expression of this marker in early-and late-stage giant cells ( Fig. 1F and J) . In addition, expression of the spongiotrophoblast-specific gene Tpbp was consistently observed in the tumors in a pattern that was nonoverlapping with Plf staining (Fig. 1M and N) .
Surprisingly, a very small cell population expressing trophoblast-specific genes was also found in tumors developed from wildtype ( Fig. 1A-D) ES cells. Unlike the Parp1-deficient tumors, however, none of the wildtype tumors formed hemorrhagic areas, and trophoblast giant cells were never seen in large aggregates interspersed with blood cells. The absolute number of cells that expressed trophoblast-specific genes in the wildtype tumors was extremely low and differed significantly from the number of positive cells in the Parp1 Ϫ/Ϫ tumors (Fig. 2) . To determine whether Parp1-deficiency caused an equal increase of different trophoblast subtypes or whether it specifically promoted giant cell differentiation, the ratios between trophoblast giant cell and spongiotrophoblast cell (Tpbp-positive) numbers were calculated. Giant cell/spongiotrophoblast ratios were on average threefold higher in Parp1 Ϫ/Ϫ tumors, suggesting a relative enhancement of trophoblast giant cell differentiation in the absence of Parp1.
Analysis of Parp1
Ϫ/Ϫ placentae Although Parp1 Ϫ/Ϫ embryos are viable, the abundance of trophoblast-derived cells and altered giant cell to spongiotrophoblast ratios in the Parp1 Ϫ/Ϫ teratocarcinoma-like tumors suggested a potential effect of Parp1-deficiency on placental development. Placentae from Parp1 Ϫ/Ϫ and wildtype embryos developed in wildtype females as well as wildtype embryos developed in Parp1 Ϫ/Ϫ mothers were analyzed at E8.5, 11.5, and 13.5 for morphological differences and expression patterns of Plf, Pl2, and Tpbp. At E8.5, morphological analysis and Plf staining suggested a slight increase in trophoblast giant cell number in some of the mutant conceptuses (data not shown). Much more evident, however, was a difference in spongiotrophoblast growth at E11.5 between placentae of wildtype and Parp1 Ϫ/Ϫ embryos. In situ hybridization with Tpbp revealed the frequent occurrence of spongiotrophoblast columns or isolated spongiotrophoblast clusters in the labyrinth region of placentae from wildtype embryos (Fig. 3) . These growth characteristics were independent of the maternal genotype, as 17/18 (94%) wildtype conceptuses developed in Parp1 ϩ/ϩ mothers and 11/14 (79%) wildtype conceptuses developed in Parp1 Ϫ/Ϫ females exhibited this pattern of spongiotrophoblast growth. In contrast, in 9/13 (69%) of the placentae from Parp1 Ϫ/Ϫ embryos, the spongiotrophoblast was thin and had a flat, sharply defined border with the underlying labyrinth ( Fig. 3E and F) . Only 4/13 (31%) placentae from Parp1 Ϫ/Ϫ conceptuses had a few isolated spongiotrophoblast cells in the labyrinth zone. Area measurements of spongiotrophoblast (as defined by the Tpbp- stained region) and total placental sizes revealed that the spongiotrophoblast fraction was significantly lower in mutant (11%) than in wildtype (14.6%) placentae (P ϭ 0.006).
Trophoblast differentiation in ES cell cultures
To determine whether trophoblast differentiation from ES cells only occurred in teratocarcinoma-like tumors, the differentiation potential of ES cells was also investigated in vitro. As judged by morphological criteria used for trophoblast stem (TS) cell cultures (Tanaka et al., 1998) , such as cell and nuclear size, perinuclear accumulation of rough endoplasmatic reticulum and a clear appearance of the cytoplasm, trophoblast giant cell-like cells were observed in both Parp1 Ϫ/Ϫ and wildtype ES cell lines (Fig. 4) . These cells characteristically developed at the margins of ES cell clumps and often appeared in small clusters, reminiscent of trophoblast giant cell differentiation in cultured TS cells. By Northern blot analysis of cells grown for 3, 5, and 7 days after plating, expression of Plf mRNA was detected by 7 days (Fig. 5) . In accordance with the findings in the tumors, levels of Plf mRNA expression were much higher in the Parp1-deficient cells. Plf mRNA expression was detected for all culture conditions tested and growth of ES cells under conditions used for growing TS cells did not enhance the extent of trophoblast gene expression. However, addition of fibroblast growth factor (bFGF), a factor essential for trophoblast stem cell maintenance (Tanaka et al., 1998) , decreased the expression of Plf mRNA (data not shown). No signals were obtained by Northern blot hybridization for Pl1, Pl2, and Tpbp (data not shown). In RNase protection assays, very low expression of the spongiotrophoblast gene Mash2 and the trophoblast stem cell gene Esrrb was detected ( Fig. 5) , but no signals were observed for Tpbp and the stem cell marker Cdx2. In contrast to Plf, transcript levels of Mash2 and Esrrb were not different between wildtype and Parp1-deficient cells and did not change significantly during the culture period. The same was true for the transcription factor Pou5f1 (Oct4) (Fig. 5) , whose expression in vivo is downregulated as the trophectoderm lineage forms (Palmieri et al., 1994) .
To prove the trophoblast identity of cells with giant cell-like morphology in the ES cell cultures, cells were subjected to in situ hybridizations with probes for the trophoblast giant cell genes Pl1, Plf, Plfr, Prlpa, and Pl2 (not shown) as well as with the spongiotrophoblast-specific gene Tpbp (Fig. 6 ). Cells with typical giant cell morphology were found to express the trophoblast giant cell genes, although Plf-expressing cells were the most frequently observed out of all giant cell-expressed genes tested (Fig. 6K) .
To investigate the heterogeneity in trophoblast giant cell numbers in the ES cell cultures, we analyzed sections of mouse implantation sites with the same probes. Whereas Plf mRNA was detected in both primary and secondary giant cells (Fig. 6B) , including those undergoing endovascular invasion (Adamson et al., 2002) , Pl1, Plfr, and Prlpa mRNAs were only detected in subpopulations of Plf-positive cells. Specifically, Pl1 mRNA expression defined primary trophoblast giant cells lining the embryonic cavity (Fig. 6A) , consistent with previous results (Carney et al., 1993) , whereas Plfr and Prlpa mRNAs were confined to secondary giant cells surrounding the ectoplacental cone ( Fig. 6C and D) . Therefore, the distribution of cells expressing the various trophoblast giant cell markers in cultured ES cells was consistent with the patterns in vivo. Overall, the number of trophoblast giant cells expressing Pl1, Plf, Plfr, and Prlpa mRNAs were all significantly higher in the Parp1-deficient cultures (Fig. 6K) . The average frequency of Plf-positive cells was 5 ϫ 10 Ϫ5 in 5-day wildtype cultures and 8.4 ϫ 10 Ϫ5 in the Parp1 Ϫ/Ϫ line. In addition to the apparent increase in trophoblast giant cell numbers, the ratio of Plf/Tpbp-expressing cells was significantly higher in the Parp1 mutant cells (13.3 in Parp1 Ϫ/Ϫ vs 9.8 in wildtype), indicating a more pronounced trophoblast giant cell differentiation consistent with the observations in the tumors.
Cell lineage-specific differentiation in Parp1-deficient ES cells
The results of the tumor and ES cell analysis clearly showed that trophoblast differentiation is promoted in the absence of Parp1. We then sought to determine whether this differentiation-promoting effect is trophoblast-specific or whether it affects cell differentiation in general. To address this question, a high-density oligonucleotide microarray analysis was carried out with wildtype and Parp1 Ϫ/Ϫ ES cell lines. A total of 128 genes/ESTs exhibited a threefold difference of expression levels (P Ͻ 0.05) between the 2 cell lines. Inspection of the lineage-specific genes on the microarray (Table 1) revealed that Parp1 Ϫ/Ϫ ES cells exhibited significant upregulation (P Ͻ 0.05) of Plf, Prlpa, and Tcfap2 (encoding transcription factor AP-2). Detection of Plf and Prlpa upregulation was consistent with the results obtained by Northern blot and in situ hybridization analysis. Although the transcription factor AP-2 is not exclusively expressed in trophoblast, it is essential for trophoblast proliferation (Werling and Schorle, 2002) and might therefore contribute to the increase in trophoblast cells in Parp1-deficient ES cells. In contrast, cell lineage-restricted markers for neuroectoderm-(Pax6, Neurog3), mesoderm-(cardiac actin/Actc1, Myod1, Nkx2-5, T/brachyury), or endoderm-(Afp, Foxa2/Hnf3b, Kdr/Flk1, Tie1) specific genes were not different between the two cell lines.
The results obtained by oligonucleotide microarray analysis were confirmed independently by Northern blot analysis of wildtype and Parp1 Ϫ/Ϫ ES cells. The genes tested included the endoderm markers Afp and Foxa2, skeletal muscle differentiation marker Myod1, cardiac marker Nkx2-5, and endothelial marker Kdr. None of these genes exhibited elevated expression levels in Parp1 Ϫ/Ϫ as compared with wildtype ES cells. Specifically, weak signals were detected for Foxa2 and Kdr but were not different between the two cell lines, whereas the other marker genes did not show any detectable expression in the cultured cells (data not shown). We concluded, therefore, that Parp1 is acting on cell differentiation in the trophoblast lineage exclusively.
Discussion
Parp1-deficiency was previously described to result in the massive accumulation of cells with giant cell morphology in ES cell-derived teratocarcinoma-like tumors developed in nude mice . We show here that these enlarged cells express definitive markers characteristic of trophoblast giant cells in normal embryonic development and thus must have differentiated from a trophectoderm precursor. This differentiation event is not dependent on the in vivo environment provided by subcutaneous injection of ES cells, because trophoblast giant cells were also detected in Parp1 Ϫ/Ϫ ES cell cultures, albeit at a frequency of only 0.01%. The expression of Tpbp, Mash2, and Esrrb provides evidence for the presence of other trophoblast subtypes in both Parp1 Ϫ/Ϫ tumors and ES cells. Remarkably, a few trophoblast derivatives were also detected in wildtype tumors and ES cells. Whereas the difference in spongiotrophoblast marker-positive cells was not significantly different between wildtype and Parp1-deficient ES cells in vitro, giant cell numbers were significantly increased in the absence of Parp1, both in cultured ES cells and in derived tumors. These data suggest that Parp1 regulates trophoblast differentiation at two stages: first, the segregation of ES cells from the trophoblast cell lineage and, second, terminal differentiation of trophoblast giant cells (Fig. 7) .
The derivation of trophoblast cells from ES cells was initially a surprise. ES cells are established from the ICM, a cell lineage that is clearly separated from the trophectoderm at the blastocyst stage. In accordance with this derivation, ES cells are capable to fully support fetal development (Nagy et al., 1990; Nagy and Rossant, 1993) . It has been noted, however, that trophoblast giant cells are commonly observed in early-passage ES cell lines (Brook and Gardner, 1997; Wiley, 1978) . When ES cells are injected into blastocysts, they mainly contribute to epiblast derivatives. However, a tiny proportion of clearly ES cell-derived giant cells has also been described (Beddington and Robertson, 1989) . Our in situ hybridizations on wildtype (J1) ES cells prove that this well-established cell line indeed harbors cells with some trophectoderm potential. According to their early differentiation during development, ES and TS cell lineages are believed to be strictly separated and controlled by different signal transduction pathways and transcriptional regulators (Rossant, 2001) . To date, manipulation of only one gene, the POU domain transcription factor Oct4 (Pou5f1), has been shown to initiate a global ES-to-TS cell switch (Nichols et al., 1998; Niwa et al., 2000) . Parp1, by contrast, has an effect only on a very small cell population, based on the fact that only up to 0.01% of cells in culture expressed trophoblast markers. The frequency of trophoblast giant cell precursors in the initial population is likely to be somewhat higher than this number, since trophoblast giant cells are postmitotic and thus are easily overgrown by the highly proliferative ES cells. Nonetheless, given the relatively modest number of trophoblast cells in the tumors and ES cell cultures, it is unlikely that Oct4 and Parp1 act in the same pathway to control ES cell fate.
A much more attractive explanation for the role of Parp1 in contributing to ES cell identity is provided by its cell death-inducing function executed in dependence of apoptosis-inducing factor (AIF) (Yu et al., 2002) . It has been proposed that a small proportion of ICM cells-and therefore also ES cells-is endowed with a "pretrophectodermal" potential and is eliminated during early development (Parchment, 1993 ). An AIF-mediated role of Parp1 in this elimination process is feasible as it was shown that programmed cell death occurring in early embryogenesis is induced by this factor (Joza et al., 2001) . Conceivably, these pretrophectodermal cells survive to a greater extent in the absence of Parp1 and represent the precursors of trophoblast giant cells and spongiotrophoblast cells that accumulate in Parp1 Ϫ/Ϫ ES cell cultures and their derived tumors. This explanation is also supported by the fact that, unlike Oct4 downregulation, Parp1-deficiency does not trigger a general switch from ES to TS cell fate, and the majority of Parp1 Ϫ/Ϫ cells retain ES cell character. In addition to the overall increase in trophoblast cell formation, Parp1-deficiency specifically resulted in the differentiation of giant cells both in vitro and in vivo. The only consistent phenotype observed in Parp1 Ϫ/Ϫ placentae was a decrease in spongiotrophoblast volume that has no overt effect on further embryonic growth, and Parp1 mutant embryos are viable and are born at expected Mendelian ratios . The reduction in spongiotrophoblast size likely reflects a skewing between spongiotrophoblast and trophoblast giant cell populations as observed in Parp1 Ϫ/Ϫ ES cells both in culture and in tumors, as the increase in trophoblast giant cells takes place on the expense of the spongiotrophoblast population. During embryogenesis, both spongiotrophoblast and (secondary) giant cells arise from a common precursor located in the ectoplacental cone. Whereas cells within the ectoplacental cone are at an intermediate stage of differentiation, cells at its margins continue to differentiate to form giant cells.
Trophoblast giant cells form by repeated rounds of DNA replication in the absence of intervening mitoses (endoreduplication). Loss of Parp1 has been reported to induce endoreduplication and hyperploidy in embryonic fibroblasts (Nozaki et al., 2001; Simbulan-Rosenthal et al., 1999) . The localization of Parp1 to centrosomes (Kanai et al., 2000) might be important for this mitosis-regulating function. Although differentiation-promoting effects have been reported in various cell lines upon Parp1 inhibition (Bauer et al., 1995; Ohashi et al., 1984) , Parp1
Ϫ/Ϫ ES cells show no enhanced differentiation of nontrophoblast cell types during tumor formation and in vitro culture. This finding was supported by the analysis of expression profiles and Northern blot hybridizations by using various cell lineage markers, demonstrating that the only lineagespecific genes consistently upregulated in the absence of Parp1 are markers of trophoblast giant cells. These data suggest an inhibitory role of Parp1 in cell differentiation that is confined, at least primarily, to the trophoblast lineage.
In conclusion, we have provided evidence for a novel role of Parp1 in suppression of a trophoblast phenotype in ES cells and ES cell-derived tumors. Lack of Parp1 results in a more pronounced differentiation of trophoblast subtypes, particularly of giant cells, that exhibit the features of cell type-specific gene expression that are characteristic of those developed in vivo.
